Skip to Content

Learn More

VICC toll-free number 1-877-936-8422

Clinical Trial VICCHN0603


Effect of PI3K Inhibition in HPV Infected Cell (deidentified)

Principal Investigator(s)

Wendell Yarbrough


  • Protocol No. VICCHN0603
  • Open Date: 04/28/2006
  • Staging: N/A
  • Age Group: Adults
  • Scope: Local
  • Objective: Analyses of HPV(+) and HPV(-) for PIK3CA mutations and amplification and expression of p100a PIK3CA can be activated by overexpression, amplification or mutation. To analyze the PIK3CA gene for mutation and amplification and determine protein expression in 20 HPV(+) and 20 HPV(-) oropharyngeal HNSCC
  • Disease Sites: Head/Neck
  • Therapies: Correlative
  • Drugs: None Specified
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT00897988
  • Secondary Protocol No: Not Specified


None Provided.


Not provided. Please call for more information.